Orzala Sharif
Overview
Explore the profile of Orzala Sharif including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ting P, Parker A, Lee J, Trussell C, Sharif O, Luna F, et al.
Nat Methods
. 2018 Oct;
15(11):941-946.
PMID: 30297964
CRISPR-Cas9 screening allows genome-wide interrogation of gene function. Currently, to achieve the high and uniform Cas9 expression desirable for screening, one needs to engineer stable and clonal Cas9-expressing cells-an approach...
2.
A Fully Automated High-Throughput Flow Cytometry Screening System Enabling Phenotypic Drug Discovery
Joslin J, Gilligan J, Anderson P, Garcia C, Sharif O, Hampton J, et al.
SLAS Discov
. 2018 May;
23(7):697-707.
PMID: 29843542
The goal of high-throughput screening is to enable screening of compound libraries in an automated manner to identify quality starting points for optimization. This often involves screening a large diversity...
3.
Johnson S, Sharif O, Mak P, Wang H, Engels I, Brinker A, et al.
Bioorg Med Chem Lett
. 2014 Jan;
24(3):786-9.
PMID: 24418775
High-throughput screening of 700,000 small molecules has identified 235 inhibitors of the GroEL/GroES-mediated refolding cycle. Dose-response analysis of a subset of these hits revealed that 21 compounds are potent inhibitors...
4.
OLeary D, Vargas L, Sharif O, Garcia M, Sigal Y, Chow S, et al.
Curr Chem Genomics
. 2010 May;
4:9-18.
PMID: 20502647
Myotonic dystrophy type 1 (DM1) is a genetic disorder characterized by muscle wasting, myotonia, cataracts, cardiac arrhythmia, hyperinsulinism and intellectual deficits, and is caused by expansion of a CTG repeat...
5.
OLeary D, Sharif O, Anderson P, Tu B, Welch G, Zhou Y, et al.
PLoS One
. 2009 Dec;
4(12):e8348.
PMID: 20020055
One therapeutic approach to Duchenne Muscular Dystrophy (DMD) recently entering clinical trials aims to convert DMD phenotypes to that of a milder disease variant, Becker Muscular Dystrophy (BMD), by employing...
6.
Sharif O, Hu H, Klock H, Hampton E, Nigoghossian E, Knuth M, et al.
Anal Biochem
. 2009 Jun;
392(2):162-8.
PMID: 19482004
Retinol-binding protein-4 (RBP4) is an emerging candidate drug target for type 2 diabetes and lipofuscin-mediated macular degeneration. The retinoic acid derivative fenretinide (N-(4-hydroxyphenyl) retinamide; HPR) exerts therapeutic effects in mouse...
7.
Breitling R, Sharif O, Hartman M, Krisans S
Eukaryot Cell
. 2002 Dec;
1(6):978-86.
PMID: 12477798
To characterize the metabolic role of peroxisomes in yeast cells under physiological conditions, we performed a comprehensive meta-analysis of published microarray data. Previous studies of yeast peroxisomes have mainly been...